.terms_of_service_block{display:block;}.terms_of_service_block.terms_btn_toggle{display:none;}

Viatris Inc. Common Stock (NASDAQ:VTRS)

Real-time price:$8.65 | Most recent change:$-0.03

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 29 March 2025

Monica McNeil

2024-05-04 04:03:33

Bullish

Quantitative fundamental analysis

In terms of stock market valuation, the major pharmaceutical sector remains at its steepest discount to the broader U.S. stock market over the past 15 years. We expect to see a unique opportunity for this discount to narrow in due course. Although the next pharmaceutical post-pandemic patent cycle from 2025 to 2030 has been top-of-mind for many U.S. stock market investors, both pipeline progression and business development across the sector leave us with only a relatively modest decrease in top-line sales revenue growth over this time frame. Further, we expect to see an upward bias to bottom-line profit margins on the basis of a mix of both further pipeline progression and capital deployment. As part of the Medicare Part B and Part D reforms and Inflation Reduction Act, U.S. medicine price hikes and limits may lift the overhang on the pharmaceutical sector. This new legislation helps re-rate both P/E and P/B multiples for many U.S. pharmaceutical companies. Our proprietary alpha stock signals skew toward Eli Lilly (LLY) and AbbVie (ABBV) with both the longest runways for EPS growth, operational performance, and attractive stock market valuation as of March 2024. The U.S. pharmaceutical companies with robust fundamental strength in animal health specialty are Zoetis (ZTS) and Horizon (HZNP). The next tier includes Merck (MRK), Pfizer (PFE), Royalty Pharma (RPRX), and Johnson & Johnson (JNJ) with some fresh incremental improvements in Tobin’s q, stock market valuation, and operational performance over the next few years.

We are constructive on these mainstream U.S. pharmaceutical companies with solid product launches and new patent development trends. Although the U.S. pharmaceutical sector may experience a modest decline in top-line sales growth in the next decade, we can expect the current patent development trends to support mid-single-digit top-line sales revenue growth for some U.S. pharmaceutical companies with rare and unique competitive advantages over the next 5-7 years. These U.S. pharmaceutical companies face few patent expirations from early-2026 to late-2029. It is reasonable for us to project more than 5% sales revenue growth per year over the next few years. A recent new product cycle combines with ongoing pipeline success for these U.S. pharmaceutical superstars. These positive trends represent potential upside value drivers to medium-term and longer-run estimates of stock market valuation for these U.S. pharmaceutical companies. In the broader context, both pipeline progression and patent development for prescription medicine should substantially improve the fundamental prospects for these superstars in the U.S. pharmaceutical sector. Beyond solid organic sales and EPS growth, we expect these superstars to leverage their ample balance sheet capacity for additional bolt-on acquisitions, cash dividends, and share repurchases. In the meantime, these U.S. pharmaceutical superstars still trade near their all-time low P/E and P/B multiples relative to the S&P 500. To the extent that this ubiquitous discount in stock market valuation tends to narrow in due course, we believe many investors can benefit substantially from this major stock market investment in some mainstream U.S. pharmaceutical companies.

The next wave of pharmaceutical patent expirations may start to emerge from 2026 to 2029. Many stock market investors continue to focus on bottom-line profit margin growth through this time frame. In time, continual pipeline traction should help gradually ease these broader concerns about stock market valuation. Whether these U.S. pharmaceutical superstars can attract higher P/E and P/B multiples remains an open controversy. The new U.S. legislation should result in more manageable target prices for medications, treatments, and therapies. As this legislation imposes upper limits on medicine prices for the elder Americans, greater demand for price-inelastic medications can help boost both sales and profits for our chosen U.S. pharmaceutical superstars.

$LLY $ABBV $PFE $MRK $BMY $GSK $RP $JNJ $ZTS $AZN $GILD $VTRS $SNY $ELAN $TMUS $T $VZ 

#size #value #momentum #profitability #assetgrowth #marketrisk #dividendyield #revenuegrowth #industry 

AYA fintech network platform https://ayafintech.network/blog/stock-synopsis-pharmaceutical-post-pandemic-patent-development-cycle/

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle - Blog - AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors.

Our chosen U.S. pharmaceutical superstars include Eli Lilly (LLY), AbbVie (ABBV), Merck (MRK), Pfize...

https://ayafintech.network/blog/stock-synopsis-pharmaceutical-post-pandemic-patent-development-cycle/

Blog+More

Leon Cooperman points out that the current Trump stock market rally now approaches normalization.

Amy Hamilton

2017-10-27 06:35:00 Friday ET

Leon Cooperman points out that the current Trump stock market rally now approaches normalization.

Leon Cooperman, Chairman and CEO of Omega Advisors, points out that the current Trump stock market rally now approaches normalization. The U.S. stock market

+See More

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations.

Chanel Holden

2018-05-06 07:30:00 Sunday ET

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations.

President Trump withdraws America from the Iran nuclear agreement and revives economic sanctions on Iran for better negotiations as western allies Britain,

+See More

House of Representatives considers a government expenditure bill with border wall finance and so sets up a shutdown stalemate with Senate.

Laura Hermes

2018-12-23 13:39:00 Sunday ET

House of Representatives considers a government expenditure bill with border wall finance and so sets up a shutdown stalemate with Senate.

The House of Representatives considers a government expenditure bill with border wall finance and therefore sets up a shutdown stalemate with Senate. As fre

+See More

Conservative Party wins the British parliamentary majority in the general election with hefty British pound appreciation.

Jonah Whanau

2020-01-08 08:25:00 Wednesday ET

Conservative Party wins the British parliamentary majority in the general election with hefty British pound appreciation.

Conservative Party wins the British parliamentary majority in the general election with hefty British pound appreciation. In response to this general electi

+See More

The Trump administration still expects to reach a Sino-U.S. trade agreement with better intellectual property protection and enforcement.

Apple Boston

2019-05-11 10:28:00 Saturday ET

The Trump administration still expects to reach a Sino-U.S. trade agreement with better intellectual property protection and enforcement.

The Trump administration still expects to reach a Sino-U.S. trade agreement with a better mechanism for intellectual property protection and enforcement. Pr

+See More

AYA fintech finbuzz analytic report on the U.S. top tech titans Fall-Winter 2019

Andy Yeh Alpha

2019-11-06 12:29:00 Wednesday ET

AYA fintech finbuzz analytic report on the U.S. top tech titans Fall-Winter 2019

Our fintech finbuzz analytic report shines fresh light on the fundamental prospects of U.S. tech titans Facebook, Apple, Microsoft, Google, and Amazon (F.A.

+See More